Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
Active, not recruiting · NCT04234568 · Registry updated 2026-09-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 | 2026-09-18 | NCT04234568 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
11 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope Comprehensive Cancer Center | Duarte | United States | 263 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Huntsman Cancer Institute/University of Utah | Salt Lake City | United States | 249 |
| Mayo Clinic Hospital in Arizona | Phoenix | United States | 120 |
| Mayo Clinic in Florida | Jacksonville | United States | 224 |
| Mayo Clinic in Rochester | Rochester | United States | 687 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| Northwestern University | Chicago | United States | 727 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |
| University of Kentucky/Markey Cancer Center | Lexington | United States | 240 |
| UPMC Hillman Cancer Center | Pittsburgh | United States | 330 |